Granulocyte colony-stimulating factor - A noninvasive regeneration therapy for treating atherosclerotic peripheral artery disease

被引:74
作者
Arai, Masazumi
Misao, Yu
Nagai, Hiroshi
Kawasaki, Masanori
Nagashima, Kenshi
Suzuki, Koji
Tsuchiya, Kunihiko
Otsuka, Setsuko
Uno, Yoshihiro
Takemura, Genzou
Nishigaki, Kazuhiko
Minatoguchi, Shinya
Fujiwara, Hisayoshi
机构
[1] Gifu Univ, Grad Sch Med, Dept Cardiol Regenerat Med & Bioeth, Gifu 5011194, Japan
[2] Gifu Univ, Grad Sch Med, Dept Transfus Med, Gifu 5011194, Japan
关键词
angiogenesis; bone marrow cells; granulocyte colony-stimulating factor; limb ischemia;
D O I
10.1253/circj.70.1093
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The purpose of this study was to determine whether treatment with granulocyte colony-stimulating factor (G-CSF), which mobilizes endothelial progenitor cells from bone marrow, can safely improve the clinical outcomes of patients with atherosclerotic peripheral artery disease (PAD). Methods and Results Thirty-nine patients with intractable PAD were randomly assigned to 3 groups: a negative control group (n=12) treated with conventional drug therapy; a positive control group (n=13) treated with conventional drug therapy plus bone marrow transplantation (BMT); and a G-CSF group (n=14) treated with conventional therapy plus subcutaneous injection of 2-5 mu g/kg of recombinant human G-CSF once daily for 10 days. One month after treatment, subjective symptoms improved significantly in the G-CSF and BMT groups. Ankle-brachial pressure index and transcutaneous oxygen pressure increased significantly in the BMT and GCSF groups, but no such improvements were seen in the group receiving conventional therapy alone. Conclusions G-CSF improves the clinical signs and symptoms of patients with intractable PAD to the same degree as BMT does. This noninvasive treatment may thus represent a useful new approach to managing the disease.
引用
收藏
页码:1093 / 1098
页数:6
相关论文
共 26 条
[1]   Isolation of putative progenitor endothelial cells for angiogenesis [J].
Asahara, T ;
Murohara, T ;
Sullivan, A ;
Silver, M ;
vanderZee, R ;
Li, T ;
Witzenbichler, B ;
Schatteman, G ;
Isner, JM .
SCIENCE, 1997, 275 (5302) :964-967
[2]  
Becker P S, 1997, Biol Blood Marrow Transplant, V3, P45
[3]  
Bensinger WI, 1996, BONE MARROW TRANSPL, V17, pS19
[4]   INVITRO AND INVIVO ACTIVATION OF ENDOTHELIAL-CELLS BY COLONY-STIMULATING FACTORS [J].
BUSSOLINO, F ;
ZICHE, M ;
WANG, JM ;
ALESSI, D ;
MORBIDELLI, L ;
CREMONA, O ;
BOSIA, A ;
MARCHISIO, PC ;
MANTOVANI, A .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (03) :986-995
[5]  
Edmonds M, 2000, DIABETES-METAB RES, V16, pS51, DOI 10.1002/1520-7560(200009/10)16:1+<::AID-DMRR142>3.0.CO
[6]  
2-S
[7]   Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection [J].
Gough, A ;
Clapperton, M ;
Rolando, N ;
Foster, AVM ;
PhilpottHoward, J ;
Edmonds, ME .
LANCET, 1997, 350 (9081) :855-859
[8]   The induction of angiogenesis by the implantation of autologous bone marrow cells: A novel and simple therapeutic method [J].
Hamano, K ;
Li, TS ;
Kobayashi, T ;
Tanaka, N ;
Kobayashi, S ;
Matsuzaki, M ;
Esato, K .
SURGERY, 2001, 130 (01) :44-54
[9]  
Harada M, 1996, J Hematother, V5, P63, DOI 10.1089/scd.1.1996.5.63
[10]  
Hill JM, 2003, CIRCULATION, V108, P478